Mercury Biopharmaceutical (ROCO:6932) 1-Year Sharpe Ratio: -0.22 (As of Sep. 12, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:6932 Mercury Biopharmaceutical Corp ROCO:6932
31 GF Score
Price NT$5.99
GF Value NT$36.00
Valuation Possible Value Trap
! 1 Warning Sign
View Full Analysis

What is Mercury Biopharmaceutical 1-Year Sharpe Ratio?

Mercury Biopharmaceutical ROCO:6932 +6.96% 31 1-Year Sharpe Ratio is -0.22 as of Sep. 12, 2026. GuruFocus rates ROCO:6932 with a GF Score™ of 31/100 and a GF Value™ of NT$36.00 (Possible Value Trap). The stock has 1 warning sign investors should review.

The 1-Year Sharpe Ratio measures the additional return that an investor receives per unit of increase in risk over the past year. As of today (2026-09-12), Mercury Biopharmaceutical's 1-Year Sharpe Ratio is -0.22.

Mercury Biopharmaceutical  (ROCO:6932) 1-Year Sharpe Ratio Explanation

The 1-Year Sharpe Ratio inidicates the risk-adjusted return of an investment over the past year. It is calculated as the annualized result of the average monthly excess return divided by its standard deviation over the past year. The monthly excess return is the monthly investment return minus the monthly risk-free rate (typically the 10-year Treasury Constant Maturity Rate). If the risk-free rate for a specific region is not available, U.S. data is used by default.

The greater a portfolio's Sharpe Ratio, the better its risk-adjusted performance. A negative Sharpe Ratio means the risk-free rate is greater than the portfolio’s historical or projected return, or else the portfolio's return is expected to be negative.

Mercury Biopharmaceutical 1-Year Sharpe Ratio Related Terms

ROCO:6932 vs ZTS: 1-Year Sharpe Ratio Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Mercury Biopharmaceutical's 1-Year Sharpe Ratio, along with its competitors' market caps and 1-Year Sharpe Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Mercury Biopharmaceutical 1-Year Sharpe Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Mercury Biopharmaceutical's 1-Year Sharpe Ratio distribution charts can be found below:

* The bar in red indicates where Mercury Biopharmaceutical's 1-Year Sharpe Ratio falls into.


ROCO:6932
31GF Score
Mercury Biopharmaceutical Corp ROCO:6932
1-Year Sharpe Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Mercury Biopharmaceutical 1-Year Sharpe Ratio Calculation

The 1-Year Sharpe Ratio measures the performance of an investment such as a stock or portfolio compared to a risk-free asset. A stock / portfolio's 1-Year Sharpe Ratio can be calculated by dividing the difference between the one-year returns of the investment and the risk-free rate, by the standard deviation of the investment returns over one year.

Frequently Asked Questions Learn more about 1-Year Sharpe Ratio →
What does a 1-Year Sharpe Ratio of -0.22 mean?
Mercury Biopharmaceutical (ROCO:6932) has a 1-Year Sharpe Ratio of -0.22 as of Sep. 12, 2026. 1-Year Sharpe Ratio measures the additional return that an investor receives per unit of increase in risk. View historical data for Mercury Biopharmaceutical and its competitors.
Is Mercury Biopharmaceutical's 1-Year Sharpe Ratio too high?
Mercury Biopharmaceutical's current 1-Year Sharpe Ratio is -0.22. Overall, Mercury Biopharmaceutical has a GF Score™ of 31/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Mercury Biopharmaceutical's 1-Year Sharpe Ratio compare to ZTS?
Mercury Biopharmaceutical's 1-Year Sharpe Ratio of -0.22 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 1-Year Sharpe Ratio for a Drug Manufacturers company?
A good 1-Year Sharpe Ratio depends on the Drug Manufacturers industry context. However, 1-Year Sharpe Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 1-Year Sharpe Ratio mean?
A high 1-Year Sharpe Ratio can signal that a stock is expensive relative to its fundamentals. 1-Year Sharpe Ratio measures the additional return that an investor receives per unit of increase in risk. View historical data for Mercury Biopharmaceutical and its competitors. Mercury Biopharmaceutical's current 1-Year Sharpe Ratio is -0.22. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mercury Biopharmaceutical stock overvalued right now?
Based on GuruFocus' analysis, Mercury Biopharmaceutical (ROCO:6932) is currently considered Possible Value Trap. The stock's GF Value™ is NT$36.00, compared to a current price of NT$5.99 — trading 83.4% below its estimated fair value. The current 1-Year Sharpe Ratio is -0.22. Mercury Biopharmaceutical's overall GF Score™ is 31/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 1-Year Sharpe Ratio calculated?
1-Year Sharpe Ratio is calculated from a company's financial statements. For Mercury Biopharmaceutical (ROCO:6932), the current 1-Year Sharpe Ratio is -0.22 as of Sep. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Mercury Biopharmaceutical (ROCO:6932) Overvalued in 2026?

Based on GuruFocus' analysis, Mercury Biopharmaceutical stock appears to be undervalued. The current stock price of NT$5.99 is trading 83.4% below its estimated GF Value™ of NT$36.00. GuruFocus considers Mercury Biopharmaceutical to be Possible Value Trap.

Key valuation signals for ROCO:6932:

  • 1-Year Sharpe Ratio: -0.22
  • GF Value™: NT$36.00 vs. price of NT$5.99 (83.4% below fair value)
  • GF Score™: 31/100 with 1 warning sign

No single metric tells the full story. See the ROCO:6932 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Mercury Biopharmaceutical Business Description

Address No. 653-1, Bannan Road, 15th Floor, Zhonghe District, New Taipei City, TWN
Mercury Biopharmaceutical Corp focuses on the development of drugs for unmet medical needs. It offers a development platform focusing on rapid release and free adjustable doses. Its 3D powder bonding method (binder jetting) combines powder and special molding adhesive and stacks them in layers.
31GF Score

Get the complete analysis for ROCO:6932

1-Year Sharpe Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$5.99
Price
NT$36.00
GF Value